| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 02/14/2002 | WO2002012307A1 Urocortin proteins and uses thereof |
| 02/14/2002 | WO2002012286A2 Stress proteins and peptides and methods of use thereof |
| 02/14/2002 | WO2002012258A1 New immunoeffector compounds |
| 02/14/2002 | WO2002012239A1 Benzimidazole derivatives, preparation and therapeutic use thereof |
| 02/14/2002 | WO2002012238A2 2-(4-PYRIDYL)AMINO-6-DIALKOXYPHENYL-PYRIDO[2,3-d]PYRIMIDIN-7-ONES |
| 02/14/2002 | WO2002012235A1 1,4-dihydropyridines as bradykinin antagonists |
| 02/14/2002 | WO2002012234A1 Tartrate salts of thiazolidinedione derivative |
| 02/14/2002 | WO2002012233A1 Tartrate salts of thiazolidinedione derivative |
| 02/14/2002 | WO2002012232A1 Tartrate salt of thiazolidinedione derivative |
| 02/14/2002 | WO2002012231A1 Tartrate salts of thiazolidinedione derivative |
| 02/14/2002 | WO2002012228A1 Cinnoline compounds |
| 02/14/2002 | WO2002012227A2 Indole, azaindole and indazole derivatives having vegf inhibiting activity |
| 02/14/2002 | WO2002012226A1 Quinoline derivatives having vegf inhibiting activity |
| 02/14/2002 | WO2002012210A1 Biphenyl derivatives and their use as ppar-gamma receptor activators |
| 02/14/2002 | WO2002012191A1 Cyclic amine derivatives and use thereof |
| 02/14/2002 | WO2002012182A1 3-methyl-20-epi-vitamin d derivatives |
| 02/14/2002 | WO2002012178A1 Compounds acting as melanocortin receptor ligands |
| 02/14/2002 | WO2002012177A1 Composition of metformin with succinic acid or salts thereof and method for treating diabetes |
| 02/14/2002 | WO2002012168A1 Novel n-(2-phenyl-3-aminopropyl)naphtamides |
| 02/14/2002 | WO2002011722A1 Substituted and non-substituted benzooxathiazoles and compounds derived therefrom |
| 02/14/2002 | WO2002011721A1 Pharmaceutical composition comprising metformin and a 5-phenoxyalkyl-2,4-thiazolidinedione-type derivative |
| 02/14/2002 | WO2002011716A2 Liquid formulation of metformin |
| 02/14/2002 | WO2002011715A2 The use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands |
| 02/14/2002 | WO2002011714A2 Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states |
| 02/14/2002 | WO2002011713A2 Methods of treating bone cancer and the pain associated therewith using endothelin antagonists |
| 02/14/2002 | WO2002011710A2 Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| 02/14/2002 | WO2002011708A2 Methods for inducing apolipoprotein e secretion |
| 02/14/2002 | WO2002011704A2 Use of aryl-substituted 1,1-diphosphonates for the treatment of bone diseases |
| 02/14/2002 | WO2002011564A2 Supplement for type 2 diabetes or lipodystrophy |
| 02/14/2002 | WO2002011562A2 Nutritional supplement for the management of weight |
| 02/14/2002 | WO2002011551A2 Oil/fat composition |
| 02/14/2002 | WO2001081415A9 Parathyroid hormone and parathyroid hormone-related protein antagonists |
| 02/14/2002 | WO2001072328A3 Methods of treating diseases with activated protein c |
| 02/14/2002 | WO2001068603A3 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl iv, processes for their preparation, and their use |
| 02/14/2002 | WO2001062954A8 Stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents |
| 02/14/2002 | WO2001044489A3 Galactomannan oligosaccharides and methods for the production and use thereof |
| 02/14/2002 | WO2001042288A3 G-protein coupled receptors |
| 02/14/2002 | WO2001032695A3 MODULATION OF eNOS ACTIVITY AND THERAPEUTIC USES THEREOF |
| 02/14/2002 | US20020019563 A S-(2-(1-iminoethyl)amino)ethyl)-2-methyl-L-cysteine |
| 02/14/2002 | US20020019534 Gem substituted hydroxamic acids |
| 02/14/2002 | US20020019533 Piperidine derivatives and anti-platelet agents containing the same |
| 02/14/2002 | US20020019526 Pyrrolo[2,3-d]pyrimidine compounds |
| 02/14/2002 | US20020019523 Dietetics; antidabetic agents; sexual disrders |
| 02/14/2002 | US20020019424 1-sulfonyl pyrrolidine derivatives |
| 02/14/2002 | US20020019411 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| 02/14/2002 | US20020019406 9H-pyrimido[4,5-b]indole derivatives: CRF1 specific ligands |
| 02/14/2002 | US20020019402 Integrin inhibitors and their methods of use |
| 02/14/2002 | US20020019396 Pharmaceutically active morpholinol |
| 02/14/2002 | US20020019393 Treating inflammation, autoimmune diseases, destructive bone disorders, proliferative disorders, infections, neurvous system disorders, reperfusion/ischemia in stroke, cardiovascular disorders, hypoxia, edema, fever, pain |
| 02/14/2002 | US20020019392 By administering indole compounds such as 1-(4-(2-Azepan-1yl-ethoxy)-benzyl)-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5 -ol; epilepsy, asthma, eating disorders, obesity, neurodegenertive conditions, schizophrenia |
| 02/14/2002 | US20020019380 1-(6-((dimethylamino)methyl)-1-methyl-2,3,5,6-tetrahydro-1H -cyclobuta(f)indol-6-yl)cyclohexanol, for example; treating psychological disorders such as depression, panic attacks, phobias, drug abuse, as well as obesity and bulemia |
| 02/14/2002 | US20020019334 Nutritional intervention composition for enhancing and extending satiety |
| 02/14/2002 | US20020019043 Treating inflammatory bowel disease in humans; obtain human, administer drug, monitor for reduction in side effects from gastrointestinal disorder |
| 02/14/2002 | US20020019000 Polynucleotides coexpressed with matrix-remodeling genes |
| 02/14/2002 | US20020018988 In silico screening |
| 02/14/2002 | US20020018818 Plant extract; boiling extraction |
| 02/14/2002 | US20020018811 Application of phytosteroids(and isomers thereof), folic acid, cyanocobalamine and pyridoxine in dietetic (alimentary) fibers |
| 02/14/2002 | US20020018807 Mixture of cocoa plant extract and antichloesterol agent |
| 02/14/2002 | US20020018787 Synergistic mixture of dimethylglycine and mussel extract |
| 02/14/2002 | US20020018773 Using lipase |
| 02/14/2002 | US20020018770 Method for administering viable microorganism composition for poultry |
| 02/14/2002 | DE10038640A1 Präparat mit gefäßschützender und antioxidativer Wirkung sowie dessen Verwendung Preparation with vascular protective and antioxidant activity and its use |
| 02/14/2002 | CA2423519A1 A new slit-like protein obtained from a cdna library from hs-5 stromal cell line |
| 02/14/2002 | CA2418951A1 Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states |
| 02/14/2002 | CA2418895A1 Biphenyl derivatives and their use as ppar-gamma receptor activators |
| 02/14/2002 | CA2418445A1 Stress proteins and peptides and methods of use thereof |
| 02/14/2002 | CA2418144A1 Urocortin proteins and uses thereof |
| 02/14/2002 | CA2417883A1 Pharmaceutical composition comprising metformin and a 5-phenoxyalkyl-2,4-thiazolidinedione-type derivative |
| 02/14/2002 | CA2417829A1 Tartrate salts of thiazolidinedione derivative |
| 02/14/2002 | CA2417828A1 Tartrate salts of thiazolidinedione derivative |
| 02/14/2002 | CA2417827A1 Tartrate salt of thiazolidinedione derivative |
| 02/14/2002 | CA2417818A1 L(+) tartrate salt of thiazolidinedione derivative |
| 02/14/2002 | CA2417769A1 Drug metabolizing enzymes |
| 02/14/2002 | CA2417755A1 Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| 02/14/2002 | CA2417606A1 Use of aryl-substituted 1,1-diphosphonates for the treatment of bone diseases |
| 02/14/2002 | CA2417587A1 Transporters and ion channels |
| 02/14/2002 | CA2417098A1 The use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands |
| 02/14/2002 | CA2416767A1 Liquid formulation of metformin |
| 02/14/2002 | CA2416525A1 Indole, azaindole and indazole derivatives having vegf inhibiting activity |
| 02/14/2002 | CA2415469A1 Quinoline derivatives having vegf inhibiting activity |
| 02/14/2002 | CA2415467A1 Novel n-(2-phenyl-3-aminopropyl)naphtamides |
| 02/14/2002 | CA2415022A1 Cinnoline compounds |
| 02/14/2002 | CA2412368A1 Benzimidazole derivatives, preparation and therapeutic use thereof |
| 02/13/2002 | EP1179350A2 Encapsulated cell system for implantation into the human CNS |
| 02/13/2002 | EP1179348A2 Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases |
| 02/13/2002 | EP1179343A1 Remedies for diabetes |
| 02/13/2002 | EP1179065A2 Full-length molecules expressed in human tissues |
| 02/13/2002 | EP1179064A2 Secreted polypeptides and corresponding polynucleotides |
| 02/13/2002 | EP1179005A1 Steroid compounds with a c17-alkyl side chain and an aromatic a-ring for use in therapy |
| 02/13/2002 | EP1178993A1 Thiazoloderiatives and pharmaceutical compositions containing them |
| 02/13/2002 | EP1178984A2 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives |
| 02/13/2002 | EP1178981A1 Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods |
| 02/13/2002 | EP1178977A1 Ion channel modulating agents |
| 02/13/2002 | EP1178973A2 Novel compounds, their use and preparation |
| 02/13/2002 | EP1178966A1 Quinoline derivatives as inhibitors of mek enzymes |
| 02/13/2002 | EP1178963A1 Ion channel modulating agents |
| 02/13/2002 | EP1178962A1 Process for the preparation of paroxetine acetate and analogues thereof |
| 02/13/2002 | EP1178958A2 N-cyanomethyl amides as protease inhibitors |
| 02/13/2002 | EP1178952A1 NOVEL INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR-$g(a) MODULATORS, SYNTHESES OF SAID MODULATORS AND METHODS OF USING SAID MODULATORS |
| 02/13/2002 | EP1178809A1 Pharmaceutical composition in unit form containing acetylsalcylic acid and clopidogrel hydrogenosulphate |